misleading statements

Navan stock plunges 63% following securities fraud allegations over undisclosed $95M sales expense spike and CFO departure post-IPO.

Oracle faces class action lawsuit alleging undisclosed AI infrastructure costs and revenue mismatches. Stock declined following missed earnings, delayed data centers, and partner withdrawal.

PayPal shareholders can file claims in securities fraud class action alleging material misstatements about Branded Checkout. Stock plummeted 20.3% following surprise CEO departure and weak earnings.

Law Offices of Howard G. Smith filed securities fraud class actions against $SDM, $BRBR, $METC, and $CLEUF, alleging market manipulation and misrepresentation. Lead plaintiff deadline: late March 2026.

Varonis faces class action lawsuit over alleged concealment of 63.9% term license revenue decline. Stock crashed 48%, erasing $3.8 billion in value.

Schall Law Firm seeks Vistagen investors in class action over alleged false statements regarding fasedienol drug candidate's Phase 3 trial prospects.

Class action suits filed against Ultragenyx and Mereo BioPharma following failed Phase III trials for setrusumab, with stock prices crashing 42.32% and 87.7% respectively.

Class actions filed against BlackRock TCP and Plug Power over alleged disclosure failures—BlackRock TCP faces NAV understatement claims following 19% decline; Plug Power accused of overstating DOE funding prospects.

Robbins Geller files class action against NuScale Power for allegedly misrepresenting commercialization partner ENTRA1's nuclear experience, triggering 12% stock decline.

Class action lawsuit filed against $PLUG alleging false statements about DOE funding and hydrogen facility prospects between January and November 2025.

Class action lawsuit filed against $BSX alleging executives made false statements about U.S. electrophysiology segment sustainability, concealing competitive pressures and regulatory headwinds.

Class action lawsuit filed against BBWI alleging executives made false statements about growth strategy results. Coverage period: June 4, 2024 to November 19, 2025.

Class action lawsuit filed against $UGXY alleging securities fraud over misleading setrusumab trial data and OI patient safety disclosures.

BellRing Brands faces securities lawsuits alleging misrepresented sales growth driven by inventory stockpiling. Lead plaintiff deadline: March 23, 2026.

RegenxBio faces securities class action alleging misleading RGX-111 gene therapy claims; investors have until April 14, 2026 to file.

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability, resulting in earnings miss and weak guidance.

Rosen Law Firm urges PomDoctor investors to join securities class action alleging fraud, stock manipulation, and insider selling. April 7, 2026 lead plaintiff deadline.

Picard Medical faces securities fraud lawsuit alleging stock manipulation through social media misinformation, insider dumping, and artificial trading. Investors have until April 13, 2026 to join class action.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.